An Introduction to Pituitary Disorders
Pituitary disorders are rare and include acromegaly, adult growth hormone deficiency, craniopharyngioma, Cushing’s disease, diabetes insipidus, hypopituitarism, non-functioning tumours and prolactinoma. These conditions can be hard to diagnose, but advances in pituitary imaging technology and the development of intraoperative MRI have facilitated prompt detection. Treatments include pituitary hormone replacement, dopamine agonist therapy for the treatment of prolactin-secreting pituitary tumours and some growth hormone-secreting pituitary tumours, and somatostatin, octreotide and pegvisomant for the treatment of acromegaly. The approval of oral octreotide delayed-release capsules is set to transform the maintenance therapy of patients with acromegaly.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Pituitary Disorders Content
Seliciclib: A New Treatment for Cushing’s Disease?
touchREVIEWS in Endocrinology. 2023;20(1):1–2:Online ahead of journal publication
Cushing’s disease (CD), or pituitary-dependent Cushing’s syndrome, is almost always caused by corticotroph tumours, a type of pituitary neuroendocrine tumour, which overproduces adrenocorticotrophic hormone (ACTH), ultimately leading to hypercortisolism and its associated clinical consequences, including increased mortality.1 The complications associated with Cushing’s syndrome must be minimized through effective treatment, ideally by rapidly normalizing hypercortisolaemia.1 The most effective […]
Oral Octreotide Capsules and Paltusotine in Management of Acromegaly
touchREVIEWS in Endocrinology. 2023;20(1):Online ahead of journal publication
Acromegaly is the clinical consequence of chronic excessive exposure of the tissues to growth hormone (GH) and its second messenger, insulin-like growth factor-I (IGF-I). The excess GH secretion is almost exclusively secondary to a GH-secreting pituitary adenoma (somatotropinomas); however, excess GH also results from ectopic GH-releasing hormone (GHRH) secretion, usually from a neuroendocrine tumour, in […]
Diego Ferone, ENDO23: Efficacy and safety of octreotide subcutaneous depot in patients with acromegaly
Extended-release formulations of the somatostatin analogues, octreotide and lanreotide, are first-line medical therapies for patients with acromegaly who have contraindications for, or are not cured by, surgical intervention and/or radiotherapy. touchENDOCRINOLOGY are joined by Dr Diego Ferone (University of Genova, Italy) to discuss the efficacy and safety of CAM2029 in acromegaly evaluated in a 6-month, […]
Thierry Brue, ECE 2023: Novel and emerging therapies for acromegaly
Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. It occurs when the pituitary gland produces too much growth hormone (GH). touchENDOCRINOLOGY were delighted to speak with Prof. Thierry Brue (Aix-Marseille University, Marseille, France) about the current treatment paradigm for acromegaly and the latest therapies that are currently being developed. The abstract ‘Management […]
Multidisciplinary insights for Cushing’s disease: Individualized medical management of patients for whom surgery is not an option or not curative
Hear multidisciplinary team and patient insights on the medical management of Cushing’s disease.
Anterior Pituitary Hormones in Blood and Cerebrospinal Fluid of Patients in Neurocritical Care
touchREVIEWS in Endocrinology 2022;18(1):71–9 DOI: https://doi.org/10.17925/EE.2022.18.1.71
In physiological conditions, the pituitary gland contributes to proper body functions and homeostasis. The assumed circadian rhythm of anterior pituitary hormones seems to be an important part of the hormonal balance. Cortisol release triggered by adrenocorticotropic hormone (ACTH) forms the main part of the body’s ‘stress response’, which is crucial for a patient’s reaction to […]
Medical Therapy for Craniopharyngiomas
touchREVIEWS in Endocrinology. 2021;17(2):121–32 DOI: https://doi.org/10.17925/EE.2021.17.2.121
Craniopharyngiomas (CPs) are rare, benign, epithelial tumours of the sellar and parasellar regions arising as embryonic malformations along the pathway of the craniopharyngeal duct.1 They have an incidence of 0.13 per 100,000 per year to 0.5–2.0 per million per year and are classified as grade I tumours according to the 2017 WHO Classification of Tumors of […]
Susan Samson, ENDO 2021: Outcomes from the CHIASMA OPTIMAL Open-Label Extension Study
We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly. ‘One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly.‘ (PRESENTATION NUMBER: OR14-3) was presented at the […]
Case Report of a Rare Adrenocortical Oncocytoma Suspected to be an Adrenal Carcinoma
touchREVIEWS in Endocrinology. 2021;17(1):71–4 DOI: https://doi.org/10.17925/EE.2021.17.1.71
Oncocytomas are epithelial tumours composed of cells with eosinophilic, mitochondria-rich cytoplasm.1 They can occur in various organs, such as the kidneys, thyroid, pituitary gland, salivary glands and parathyroid glands. Rarely, it has been reported in the respiratory and gastrointestinal tracts.2–4 Adrenal oncocytomas are extremely rare, with nearly 200 published cases since Kakimoto et al. reported the first […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!